NCT02586857View on ClinicalTrials.gov

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 25, 2016

Primary Completion Date

June 26, 2020

Study Completion Date

April 1, 2026

Conditions
Glioblastoma Multiforme
Interventions
DRUG

ACP-196

Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).

Trial Locations (7)

2215

Research Site, Boston

10021

Research Site, New York

94304

Research Site, Palo Alto

98684

Research Site, Vancouver

90095-1769

Research Site, Los Angeles

02114

Research Site, Boston

02215

Research Site, Boston

Sponsors

Lead Sponsor

Acerta Pharma BV
All Listed Sponsors
lead

Acerta Pharma BV

INDUSTRY